#1 Clinical Trials Search in Europe

Iptacopan

Iptacopan, also known as LNP023, is an investigational drug being studied in clinical trials for several medical conditions. These trials aim to evaluate the safety, efficacy, and long-term effects of iptacopan in treating diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various kidney disorders. The studies involve different patient populations and treatment approaches to thoroughly assess this potential new therapy.

Table of Contents

What is Iptacopan?

Iptacopan, also known by its research code LNP023, is a new medication being developed to treat several rare blood and kidney disorders[1]. It is an oral medication, which means it can be taken by mouth, making it potentially more convenient for patients compared to some existing treatments that require injections or infusions[2].

What Diseases Does Iptacopan Treat?

Iptacopan is being studied for the treatment of several rare diseases, including:

  • Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare blood disorder where red blood cells break down faster than normal, leading to anemia, fatigue, and other complications[3].
  • Atypical Hemolytic Uremic Syndrome (aHUS): A rare condition that causes abnormal blood clots to form in small blood vessels throughout the body, which can lead to kidney failure and other organ damage[5].
  • C3 Glomerulopathy (C3G): A group of rare kidney diseases that cause inflammation and damage to the kidneys[9].
  • Immune Thrombocytopenia (ITP): A blood disorder that causes a low platelet count, which can lead to easy bruising and bleeding[2].
  • Cold Agglutinin Disease (CAD): A rare type of autoimmune hemolytic anemia where the body’s immune system mistakenly attacks and destroys its own red blood cells[2].

How Does Iptacopan Work?

Iptacopan works by targeting a specific part of the body’s immune system called the complement system. In many of the diseases that iptacopan treats, the complement system is overactive, causing damage to the body’s own cells. Iptacopan helps to reduce this overactivity, potentially slowing down or stopping the progression of these diseases[3][9].

Iptacopan in Clinical Trials

Iptacopan is currently being studied in several clinical trials to determine its safety and effectiveness. These trials are testing the drug in different patient groups and comparing it to existing treatments or placebos (inactive substances). Some key trials include:

  • A study in patients with PNH who are switching from other treatments to iptacopan[3].
  • A trial in patients with aHUS who have never received complement inhibitor therapy before[5].
  • A study in patients with C3G comparing iptacopan to a placebo[9].
  • A trial looking at the long-term safety and effectiveness of iptacopan in patients with PNH[4].

How is Iptacopan Administered?

Iptacopan is taken orally (by mouth) as a capsule. In most clinical trials, the dose being studied is 200 mg twice daily[1][3]. This means patients typically take one capsule in the morning and one in the evening. The oral administration is a potential advantage over some existing treatments that require injections or intravenous infusions.

Effectiveness of Iptacopan

Early results from clinical trials suggest that iptacopan may be effective in treating several rare diseases. For example:

  • In patients with PNH, iptacopan has shown promise in increasing hemoglobin levels (a measure of red blood cells) and reducing the need for blood transfusions[10].
  • In patients with C3G, researchers are looking at whether iptacopan can reduce protein in the urine and improve kidney function[9].
  • For patients with aHUS, studies are examining whether iptacopan can prevent the formation of blood clots and improve kidney function[5].

It’s important to note that these results are preliminary, and more research is needed to fully understand the effectiveness of iptacopan in these conditions.

Safety and Side Effects

As with any new medication, researchers are carefully studying the safety of iptacopan. So far, the drug appears to be generally well-tolerated, but all potential side effects are still being investigated[4]. Common side effects and any serious adverse events are being closely monitored in all ongoing clinical trials. Patients in these trials undergo regular check-ups and laboratory tests to ensure their safety.

Future Research and Availability

Iptacopan is still considered an investigational drug, which means it is not yet approved for general use outside of clinical trials. Researchers are continuing to study its effects in various diseases and patient populations. If the results of these studies are positive, iptacopan may become available as a treatment option in the future, pending approval by regulatory agencies like the FDA or EMA[6].

For patients interested in iptacopan, the best source of information is their healthcare provider, who can provide updates on the drug’s development and potential availability for their specific condition.

Aspect Details
Drug Name Iptacopan (LNP023)
Administration Oral capsules, typically 200 mg twice daily
Conditions Studied Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), IgA Nephropathy, C3 Glomerulopathy, Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)
Primary Outcomes Changes in hemoglobin levels, reduction in proteinuria, improvement in kidney function, absence of thrombotic microangiopathy (TMA)
Secondary Outcomes Changes in platelet count, LDH levels, eGFR, quality of life measures, safety and tolerability
Study Designs Phase 1-3 trials, including single-arm, open-label, and randomized controlled studies
Patient Populations Adults and some adolescents with various conditions, including treatment-naive and those switching from other therapies

FAQ

  • What is iptacopan? Iptacopan, also known as LNP023, is an investigational drug being studied for the treatment of various conditions, including blood disorders and kidney diseases. It is taken orally, usually twice daily.
  • What conditions is iptacopan being studied for? Iptacopan is being studied for several conditions, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), IgA nephropathy, and other kidney disorders such as C3 glomerulopathy and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
  • How is iptacopan administered? Iptacopan is typically administered orally as capsules. In most trials, the dosage is 200 mg twice daily, though some studies may use different doses or adjust based on patient characteristics.
  • What are the main goals of the iptacopan clinical trials? The main goals of the iptacopan clinical trials are to evaluate its safety, efficacy, and long-term effects in treating various conditions. Researchers are looking at how well it improves symptoms, affects disease markers, and impacts patients' quality of life compared to existing treatments or placebo.
  • Are there any known side effects of iptacopan? As iptacopan is still being studied, all potential side effects are not yet known. The clinical trials are designed to monitor for adverse events and evaluate the drug's safety profile. Patients in the trials are closely monitored for any unexpected reactions or side effects.

Ongoing Clinical Trials on Iptacopan

  • Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Greece Italy The Netherlands +1

  • Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Hungary +7

  • Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

    Recruiting

    1 1
    Investigated drugs:
    Denmark France Germany Greece Italy The Netherlands +3

  • Study on the Effectiveness and Safety of Iptacopan with Drug Combination for Adults with Active Lupus Nephritis Class III-IV, +/- V

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Hungary Portugal Spain

  • Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Greece Italy +4

  • Study on Long-Term Safety and Effects of Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

    Recruiting

    1 1 1
    Investigated drugs:
    Czechia

  • Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Hungary +6

  • Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +3

  • Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy Lithuania The Netherlands +1

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Thrombotic microangiopathy (TMA): A group of disorders characterized by small blood clots forming in small blood vessels throughout the body, potentially causing organ damage.
  • Hemoglobin: A protein in red blood cells that carries oxygen throughout the body.
  • Lactate dehydrogenase (LDH): An enzyme found in many body tissues. Elevated levels can indicate cell damage or disease.
  • Estimated glomerular filtration rate (eGFR): A measure of how well the kidneys are filtering waste from the blood.
  • Proteinuria: The presence of excess proteins in the urine, which can be a sign of kidney disease.
  • Breakthrough hemolysis (BTH): A sudden increase in the destruction of red blood cells in patients with certain blood disorders.
  • Complement system: A part of the immune system that helps or 'complements' the ability of antibodies and immune cells to clear pathogens from the body.
  • Extravascular Hemolysis (EVH): The destruction of red blood cells outside of blood vessels, typically in the liver or spleen.
  • Intravascular Hemolysis (IVH): The destruction of red blood cells within blood vessels.

References

  1. https://clinicaltrials.gov/study/NCT05078580
  2. https://clinicaltrials.gov/study/NCT05086744
  3. https://clinicaltrials.gov/study/NCT05630001
  4. https://clinicaltrials.gov/study/NCT04747613
  5. https://clinicaltrials.gov/study/NCT05889430
  6. https://clinicaltrials.gov/study/NCT05222412
  7. https://clinicaltrials.gov/study/NCT05935215
  8. https://clinicaltrials.gov/study/NCT05755386
  9. https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-iptacopan-for-patients-with-complement-3-glomerulopathy/
  10. https://clinicaltrials.gov/study/NCT04820530